Literature DB >> 2702849

Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules.

D G Menzies1, I W Campbell, A McBain, I R Brown.   

Abstract

A comparative open study of metformin unit doses of 500 mg and 850 mg was carried out in 64 obese, non-insulin dependent diabetics on 1.5 to 3 g metformin daily. Glycaemic response, blood lactate, plasma metformin concentrations and tolerance for metformin were assessed. On changing from a 500 mg unit dose to an equivalent total dose of metformin using the 850 mg preparation, there were no significant changes in the random blood glucose, glycated haemoglobin, or blood lactate concentrations. Metformin plasma concentrations remained unchanged except for patients transferred from 1.5 to 2.0 g daily to 850 mg twice daily; in these patients plasma concentrations increased from 1.83 +/- 0.87 to 2.50 +/- 0.89 micrograms/l (p less than 0.01). Seven patients (3 asymptomatic and 4 with background symptoms) became intolerant of the 850 mg regimen and required to return to the 500 mg dose regimen. After exclusion of patients intolerant of the 850 mg dose regimen (11%), the remaining patients noted no significant change in symptoms and 28% of all patients transferred to the 850 mg dose unit indicated an overall preference for this regimen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702849     DOI: 10.1185/03007998909115209

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  7 in total

Review 1.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 2.  Oral antidiabetic drug use in the elderly.

Authors:  R Bressler; D G Johnson
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

3.  Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus.

Authors:  Juliana Levy; Roberta A Cobas; Marília B Gomes
Journal:  Diabetol Metab Syndr       Date:  2010-03-18       Impact factor: 3.320

Review 4.  Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.

Authors:  C J Dunn; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

5.  Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes.

Authors:  Jin-Sun Chang; Juyoung Shin; Hun-Sung Kim; Kyung-Hee Kim; Jeong-Ah Shin; Kun-Ho Yoon; Bong-Yun Cha; Ho-Young Son; Jae-Hyoung Cho
Journal:  Diabetes Metab J       Date:  2013-02-15       Impact factor: 5.376

Review 6.  Gastrointestinal Dysfunction in Parkinson's Disease: Current and Potential Therapeutics.

Authors:  Myat Noe Han; David I Finkelstein; Rachel M McQuade; Shanti Diwakarla
Journal:  J Pers Med       Date:  2022-01-21

7.  Herbal medicine use in Thai patients with type 2 diabetes mellitus and its association with glycemic control: A cross-sectional evaluation.

Authors:  A Prasopthum; T Insawek; P Pouyfung
Journal:  Heliyon       Date:  2022-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.